Therapeutic regimens in interstitial lung disease guided by genetic screening: Fact or fiction?

European Respiratory Journal

Volumn 30, Issue 5, 2007, Pages 821-822

  Bakker, J A ^a   Bierau, J ^a   Drent, M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MERCAPTOPURINE;

DRUG EFFICACY; EDITORIAL; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; INTERSTITIAL LUNG DISEASE; PHARMACOGENETICS; PRIORITY JOURNAL;

AZATHIOPRINE; GENETIC SCREENING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; METHYLTRANSFERASES; PHARMACOGENETICS;

EID: 38849130722     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00110207     Document Type: Editorial

References (19)

1. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 2004; 71: 301-326.
2. Nemery B, Bast A, Behr J, et al. Interstitial lung disease induced by exogenous agents: factors governing susceptibility. Eur Respir J 2001; 18: Suppl. 32, 30s-42s.
3. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57: 119-137.
4. Kollek R, van Aken J, Feuerstein G, Schmedders M. Pharmacogenetics, adverse drug reactions and public health. Community Genet 2006; 9: 50-54.
5. Candelaria M, Taja-Chayeb L, Arce-Salinas C, Vidal-Milan S, Serrano-Olvera A, Dueňas-Gonzalez A. Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives. Anticancer Drugs 2005; 16: 923-933.
6. Perri D, Cole DEC, Friedman O, Piliotis E, Mintz S, Adhikari NKJ. Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase. Eur Respir J 2007; 30: 1014-1017.
7. Bakker JA, Drent M, Bierau J. Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease. Curr Opin Pulm Med 2007; 13: 458-463.
8. Cara CJ, Pena AS, Sans M, et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit 2004; 10: RA247-RA254.
9. Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics 2005; 15: 801-815.
10. Gardiner SJ, Gearry RB, Barclay ML, Begg EJ. Two cases of thiopurine methyltransferase (TPMT) deficiency -a lucky save and a near miss with azathioprine. Br J Clin Pharmacol 2006; 62: 473-476.
11. Richard VS, Al-Ismail D, Salamat A. Should we test TPMT enzyme levels before starting azathioprine? Hematology 2007; 12: 359-360.
12. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667-1671.
13. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-537.
14. Op den Buijsch RA, Christiaans MH, Stolk LM, et al. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 2007; 21: 427-435.
15. van Dieren JM, van Vuuren AJ, Kusters JG, Nieuwenhuis EE, Kuipers EJ, van der Woude CJ. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut 2005; 54: 1664.
16. Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 593-599.
17. Bierau J, Lindhout M, Bakker JA. The pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics 2007; (In press).
18. Clunie GP, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology 2004; 43: 13-18.
19. Priest VL, Begg EJ, Gardiner SJ, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 2006; 24: 767-781.